Previous 10 | Next 10 |
3 Hot Penny Stocks to Add to Your Watchlist Now With so many penny stocks to add to your watchlist right now, how do you know which ones to pick? It’s tough to make money with penny stocks these days. Many experts are trading with a high degree of cautious optimism. The m...
The shares of clinical-stage biotech Regulus Therapeutics Inc. ( NASDAQ: RGLS ) climbed ~15% in the pre-market trading Monday after the company announced topline data from its Phase 1 Single-Ascending Dose (SAD) trial for kidney disease candidate RGLS8429. RGLS8429, de...
Regulus Therapeutics Announces Positive Topline Safety and Pharmacokinetic (PK) Data from the Phase 1 Single-Ascending Dose (SAD) Clinical Trial of RGLS8429 for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire Phase 1b Multiple Asce...
The following slide deck was published by Regulus Therapeutics Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Regulus Therapeutics Inc. 2022 Q2 - Results - Earnings Call Presentation
Regulus Therapeutics to Participate in Upcoming Investor Conferences PR Newswire SAN DIEGO , Sept. 2, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicin...
Regulus Therapeutics, Inc. (RGLS) Q2 2022 Earnings Conference Call August 11, 2022, 05:00 PM ET Company Participants Crispina Calsada - CFO Joseph Hagan - President & CEO Conference Call Participants Yi Chen - H.C. Wainwright & Co. Presentat...
Regulus Therapeutics press release ( NASDAQ: RGLS ): Q2 GAAP EPS of -$0.50 (vs. -$0.78 Y/Y). As of Jun. 30, Regulus had $47.5M in cash, cash equivalents and marketable securities. For further details see: Regulus Therapeutics GAAP loss per share narrows
Regulus Therapeutics Reports Second Quarter 2022 Financial Results and Recent Updates PR Newswire IND accepted and first subject dosed in the Phase 1 Single-Ascending Dose (SAD) study of RGLS8429 for the treatment of Autosomal Dominant Polycystic Kidney Disease (AD...
Regulus Therapeutics Announces Timing for Second Quarter 2022 Financial Results Webcast and Conference Call PR Newswire SAN DIEGO , Aug. 4, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery...
Gainers: Inotiv ( NOTV ) +18% . IO Biotech ( IOBT ) +16% . SOPHiA GENETICS ( SOPH ) +10% . Apyx Medical ( APYX ) +9% . Rhythm Pharmaceuticals ( RYTM ) +9% . Losers: Regulus Therapeutics ( RGLS ) -14% . Aerovate...
News, Short Squeeze, Breakout and More Instantly...
Regulus Therapeutics Inc. Company Name:
RGLS Stock Symbol:
NASDAQ Market:
Regulus Therapeutics Inc. Website:
Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire Continued mechanistic dose resp...
Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® Indexes PR Newswire SAN DIEGO , June 4, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and devel...
Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer PR Newswire SAN DIEGO , May 16, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of inn...